Tartaric Acid
Medchemexpress LLC Fobrepodacin disodium | 1384984-20-6 | 99.5% | C21H24FN6Na2O6P | 10MG
Fobrepodacin disodium is the disodium phosphate prodrug of an aminobenzimidazole gyrase B/ParE inhibitor. It is an orally bioavailable antibacterial agent that demonstrates potent bactericidal activity in preclinical in vivo models, including mycobacterial infection studies. Supplied as a white to off-white solid, it is intended for research use in drug discovery and efficacy experiments.
- Orally bioavailable phosphate prodrug
- Potent bactericidal activity in vivo
- Suitable for preclinical efficacy and pharmacology studies
- White to off-white solid, convenient for formulation
- High purity (99.5%) for reproducible results
eMolecules L-(+)-Tartaric acid di-n-butyl ester | 87-92-3 | MFCD00009443 | 1g
Combi-Blocks | L-(+)-Tartaric acid di-n-butyl ester | 1g | 374521995 | QE-7161 | 95.000 | 87-92-3 | MFCD00009443 | 262.302 | C12H22O6
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Bioworld L-(+)-Tartaric Acid, 10% (w/v), 1 L
L-(+)-Tartaric Acid Solution 10% (w/v) in biotechnology grade water.Appearance: LiquidBoiling Point : 399.3°CDensity : ~1.9 g/cm3 (Predicted)Melting Point: 170-172 °C(lit.)RTECS Number: WW7875000
Medchemexpress LLC 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine | 934353-76-1 | MFCD16619371 | 100.0% | 375.47 | 10 MG
ENMD-2076 is a multi-targeted kinase inhibitor that selectively binds to and inhibits tyrosine and Aurora kinases. This action can lead to the inhibition of cell division and proliferation, and may induce apoptosis in tumor cells. It also exhibits antiangiogenic activity, making it suitable for various research applications.
- Inhibits multiple kinases including Aurora A, Flt3, KDR/VEGFR2, and FGFR1.
- Demonstrates antiproliferative activity against human cell lines.
- Induces G2-M-phase arrest and apoptosis.
- Inhibits Flt3 ligand (FL)-induced Flt3 autophosphorylation.
- Inhibits VEGFR2/KDR autophosphorylation.
- Shows dose-dependent inhibition of tumor growth in vivo.
Medchemexpress LLC DL-Tartaric acid | 133-37-9 | 98.0% | 150.09 | C4H6O6 | 500g
DL-Tartaric acid is an orally active and non-racemic mixture of L- and D-tartaric acid with antioxidant activity 14C-labeled DL-Tartaric acid is nephrotoxic[1][2][3]
Medchemexpress LLC DL-Tartaric acid | 133-37-9 | MFCD00071626 | 98.0% | 150.09 g/mol | C4H6O6 | 250g
DL-Tartaric acid is an orally active and non-racemic mixture of L- and D-tartaric acid with antioxidant activity 14C-labeled DL-Tartaric acid is nephrotoxic[1][2][3]
Chem-Impex International, Inc. (+)-O,O'-Di-p-toluoyl-D-tartaric acid | 32634-68-7 | MFCD00008552 | 1KG
(+)-O,O'-Di-p-toluoyl-D-tartaric acid, 32634-68-7, MFCD00008552, 1KG
Medchemexpress LLC ENMD-2076 Tartrate | 1453868-32-0 | 99.7% | 525.56 | 10 MG
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. It is for research use only and not sold to patients.
- Acts as a multi-targeted kinase inhibitor
- Inhibits Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, and PDGFRα
- Shows selective inhibition of Aurora A over Aurora B
- Inhibits human umbilical vein endothelial cell (HUVEC) growth
- Blocks cellular Flt3 ligand (FL)-induced Flt3 autophosphorylation
- Prevents stem cell factor (SCF)-induced Kit autophosphorylation
- Inhibits VEGFR2/KDR autophosphorylation
- Demonstrates dose-dependent inhibition of tumor growth or tumor regression in vivo
- Exhibits good tolerance in daily doses during in vivo studies
Sigma Aldrich Fine Chemicals Biosciences (-)-O,O'-Dibenzoyl-L-tartaric acid monohydrate >=99.0% (T) | 62708-56-9 | MFCD00149119 | 100G
(-)-O,O'-Dibenzoyl-L-tartaric acid monohydrate >=99.0% (T) | Purity: >=99.0% (T) | Mol Wt: 376.31 | 62708-56-9 | MFCD00149119 | 100G
Medchemexpress LLC ENMD-2076 Tartrate | 1453868-32-0 | 99.66% | 525.56 | 50 MG
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor primarily targeting Aurora A, Flt3, and VEGFR2. It is intended for research use only and not for patient applications. This compound is known for its inhibitory effects on various kinases, contributing to its potential in anti-proliferative and anti-angiogenic research.
- Exhibits potent inhibition of Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, and PDGFRα.
- Induces G2-M-phase arrest and apoptosis in U937 cells.
- Inhibits Flt3 and Kit autophosphorylation.
- Shows dose-dependent inhibition of tumor growth in vivo.
Medchemexpress LLC HY-N2522 5mg Medchemexpress, Carboxyatractyloside (dipotassium) CAS:33286-30-5 Purity:>98%
Medchemexpress, HY-N2522 5mg Carboxyatractyloside (dipotassium) CAS:33286-30-5 Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Apexbio Technology LLC ENMD-2076 934353-76-1 5mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies